Viking, Other Hedge Funds Eye Biopharma IPO

Investors may not be too excited about the new issues market, however.

Nicky Loh/Bloomberg

Nicky Loh/Bloomberg

A slew of hedge funds led by Viking Global Investors are gearing up for perhaps the first biopharma initial public offering of the year.

Given 2021’s rough ride for IPOs, however, investor enthusiasm about new issues may not be very high, at least not for now.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.